Literature DB >> 3079785

A group-specific inhibitor of lysosomal cysteine proteinases selectively inhibits both proteolytic degradation and presentation of the antigen dinitrophenyl-poly-L-lysine by guinea pig accessory cells to T cells.

S Buus, O Werdelin.   

Abstract

A limited intralysosomal proteolytic degradation is probably a key event in the accessory cell processing of large protein antigens before their presentation to T cells. With the aid of highly specific inhibitors of proteinases, we have examined the role of proteolysis in the presentation of antigens by guinea pig accessory cells. The proteinase inhibitor benzyloxycarbonyl-phenylalanylalanine-diazomethyl-ketone, which selectively inhibits cysteine proteinases, was used to block this set of enzymes in cultured cells. We demonstrate that the selective inhibition of the cysteine proteinases of antigen-presenting cells causes a profound inhibition of both the proteolytic degradation and the presentation of the synthetic antigen dinitrophenyl-poly-L-lysine. In contrast, the presentation of another synthetic antigen, the copolymer of L-glutamic acid and L-alanine, was enhanced by the same inhibitor. Another inhibitor, pepstatin A, which selectively blocks aspartic proteinases, did not block the presentation of dinitrophenyl-poly-L-lysine. The results identify cysteine proteinases, probably lysosomal, as one of the groups of enzymes involved in antigen processing.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079785

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Proteolytic fragmentation of tetanus toxin by subcellular fractions of JY, a B lymphoblastoid cell line.

Authors:  A Reboul; J Arvieux; J F Wright; M G Colomb
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

2.  Localization of MHC class II molecules in murine bone marrow-derived macrophages.

Authors:  T Lang; J C Antoine
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 3.  Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus.

Authors:  C J Hackett; L C Eisenlohr
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

4.  Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing.

Authors:  R M Hershberg; P E Framson; D H Cho; L Y Lee; S Kovats; J Beitz; J S Blum; G T Nepom
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  Endopeptidase activities associated with the plasma membrane compartment of an antigen-presenting B cell.

Authors:  B M Chain; G Bou-Gharios; I Olsen
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

6.  Obligatory role of macrophages in dengue virus antigen presentation to B lymphocytes.

Authors:  N Rizvi; U C Chaturvedi; A Mathur
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

7.  Processing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases.

Authors:  M A Holsti; P M Allen
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

8.  Interaction between a "processed" ovalbumin peptide and Ia molecules.

Authors:  S Buus; S Colon; C Smith; J H Freed; C Miles; H M Grey
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Processing and presentation of tetanus toxin by antigen-presenting cells from patients with chronic granulomatous disease (CGD) to human specific T cell clones are not impaired.

Authors:  C Barbey; J M Tiercy; N Fairweather; H Niemann; R Seger; G Corradin
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

10.  Presentation of cartilage proteoglycan to a T cell hybridoma derived from a mouse with proteoglycan-induced arthritis.

Authors:  F R Brennan; G Negroiu; E I Buzás; C Fülöp; K Holló; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.